Physician profile
Glenn Poon
NPI 1508845629
$14,972.17
in general payments reported to CMS, 2019-2025
51 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $1,382 · 2021: $2,719 · 2022: $2,291 · 2023: $2,289 · 2024: $2,592 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,995.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,002.77 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,138.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,126.77 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.96 | 2019-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $765.52 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Boston Scientific Corporation | $751.78 | 2021 | |
| Lilly USA, LLC | $695.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $555.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $552.77 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Shield Therapeutics INC | $536.98 | 2023-2025 | Accrufer |
| Sanofi-Aventis U.S. LLC | $522.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $513.65 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.11 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $416.59 | 2019-2025 | |
| Amgen INC. | $398.60 | 2019-2025 | Repatha, Otezla, Otezla |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $379.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $285.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.76 | 2019-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $196.51 | 2019-2023 | Seglentis, Livalo |
| Corcept Therapeutics | $192.62 | 2022-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.16 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $189.61 | 2023-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $172.76 | 2022-2025 | Rexulti, Vyepti |
| Exact Sciences Corporation | $169.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $164.26 | 2024-2025 | Auvelity |
| Amarin Pharma, INC. | $157.77 | 2019-2021 | |
| Esperion Therapeutics, INC. | $152.65 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $151.25 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Idorsia Pharmaceuticals US INC | $139.85 | 2022-2024 | Quviviq |
| Nestle Healthcare Nutrition INC. | $107.08 | 2020-2022 | |
| Mylan Specialty L.P. | $80.47 | 2019-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company Ltd. | $74.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.63 | 2021-2022 | |
| Biogen, INC. | $63.47 | 2021-2022 | |
| Genentech USA, INC. | $54.54 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $51.23 | 2024-2025 | Fanapt |
| Abbott Laboratories | $50.03 | 2020-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $48.25 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $39.21 | 2020 | |
| Xeris Pharmaceuticals, INC. | $38.89 | 2024-2025 | Gvoke Hypopen |
| Hikma Pharmaceuticals USA | $38.33 | 2021 | |
| Eyevance Pharmaceuticals LLC | $38.33 | 2021 | |
| Scilex Pharmaceuticals INC. | $36.34 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $31.81 | 2024-2025 | Uptravi, Opsumit |
| Medtronic, INC. | $17.77 | 2023 | Venaseal |
| Ironshore Pharmaceuticals INC. | $17.66 | 2019 | |
| Cranial Technologies, INC | $16.81 | 2024 | Doc Band |
| Tactile Systems Technology INC | $16.39 | 2022 | |
| Smith+Nephew, INC. | $13.36 | 2024 | Collagenase Santyl |
| Biohaven Pharmaceuticals, INC. | $11.70 | 2021 | |
| Eisai INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.